Hard to Treat Diseases Announce Agreement With Chilean Government for Shipment of Vaccines

Rochester, New York 11/19/2009 08:25 PM GMT (TransWorldNews)

Hard to Treat Diseases (HTDS.PKS) and their China subsidiary Mellow Hope have announced that the first shipment of H1N1 Influenza A Vaccine for Chilean market has been agreed upon with the Chilean government. The export license has already been applied for and the vaccine will be shipped shortly.

Penny Stock Professor, a leading financial publication, is pleased to alert investors of stocks on the move. Sign Up for our Free Penny Stock Picks.

Prior this week the Chilean Institute of Public Health had issued the Registration Certificate for Mellow Hope's H1N1 Influenza A Vaccine. The government of Chile has already secured the first order of 200,000 doses and believes a total of 4-6 million doses may be needed. The total value of the first shipment is approximately $1.8 million.

Hard to Treat Diseases (HTDS) operates two medical subsidiaries in Europe and Mainland China. HTDS is a parent company with operations in East European Serbia based pharmaceutical company Slavica Bio Chem Co and in China Mellow Hope Inc.

Sign up for the free Penny Stock Professor newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.

About Us

Penny Stock Professor is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.

Please click here to read the full disclaimer.